Novavax stock surges after resolving Gavi vaccine dispute
02/23/2024 04:10
Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi's payment for COVID-19 vaccines that were not delivered. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
Barrons.com
Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.
Novavax was rising sharply Thursday after the vaccine maker reached a settlement with nongovernmental organization Gavi for its Covid-19 vaccine. Novavax said in a news release Thursday that it had reached a settlement related to a 2021 advance purchase agreement for its prototype Covid-19 vaccine. Gavi is an international organization that works to improve access to vaccines for children in lower-income countries.